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Study Objective. To evaluate the efficacy, safety, and costs of rabbit
antithymocyte globulin (TMG) induction in patients who received kidney
transplants from living unrelated donors.
Design. Retrospective cohort study.
Setting. Large academic medical center.
Patients. Eighty-seven patients who received kidney transplants from living
unrelated donors: 40 of the recipients underwent transplantation between
January 1, 2003, and December 31, 2004, and did not receive TMG
induction (no induction group); 47 underwent transplantation between
January 1, 2005, and June 30, 2006, and received TMG induction (induc-
tion group). All patients received cyclosporine-based immunosuppression.
Measurements and Main Results. Biopsy-proven acute rejection,
posttransplantation complications, and inpatient hospital costs for the first
12 months after transplantation were compared between groups using
standard univariate statistical analyses. Induction significantly decreased
the occurrence of biopsy-proven acute rejection versus no induction (2% vs
48%, p<0.001). Fifty percent of rejection episodes in the no induction
group required hospitalization, and 46% of rejection episodes required
TMG treatment. Slightly elevated initial costs associated with TMG
induction were offset by lower costs related to rejection treatment. Total
inpatient costs for the 12 months after transplantation were comparable
between the groups (no induction $66,038 vs induction $74,183, p>0.05).
For the no induction versus induction groups, no significant differences in
cytomegalovirus disease (5% vs 6%), malignancy (3% vs 2%), graft failures
(5% vs 6%), mortality (5% vs 4%), and serum creatinine concentrations
(mean ± SD 1.4 ± 0.3 vs 1.5 ± 0.3 mg/dl) were observed at 12 months
(p>0.05 for all comparisons).
Conclusion. Five-day TMG induction effectively reduced the 1-year acute
rejection rate without significantly increasing total inpatient costs or
posttransplantation complications among recipients of kidney transplants
from living unrelated donors.
Key Words: rabbit antithymocyte globulin, Thymoglobulin, living unrelated
donor kidney transplantation, rejection, cost.
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Living-donor kidney transplantation has
become a valuable treatment option for end-stage
renal disease, and it provides considerable benefits
over deceased-donor kidney transplantation.
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These benefits include shorter time on the
waiting list and improved graft and patient
survival.1, 2 Living kidney donation is not limited
to donor-recipient pairs of biologic linkages. In
fact, biologically unrelated donors account for
approximately 35% of living kidney donations in
the United States.1 The risk of acute rejection
was perceived to be lower for living-donor
transplant recipients than for deceased-donor
transplant recipients, but several studies have
provided evidence to the contrary.3–6 In
particular, living unrelated transplant recipients
had higher rejection rates compared with those of
deceased-donor recipients and living related-
donor transplant recipients who were given
similar maintenance immunosuppression.4–6
Acute rejection is a common complication of
transplantation that markedly affects long-term
clinical and economic outcomes. Patients who
experience an episode of acute rejection are more
likely to develop chronic rejection and graft
failure.7–9 This relationship between acute
rejection and long-term graft outcome has been
shown in all donor types.4, 9 Acute rejection is
also associated with substantial increases in
treatment costs and hospitalizations.10, 11 As an
approach to reduce the acute rejection rate,
antibody induction is commonly used to
intensify initial immunosuppression in kidney
transplant recipients.
Several prospective, randomized, controlled
clinical trials demonstrated that induction with
rabbit-derived polyclonal antithymocyte globulin
(Thymoglobulin; Genzyme Corp., Cambridge,
MA) reduced the rate and severity of acute
rejection compared with no induction or with the
use of horse-derived polyclonal antithymocyte
globulin or basiliximab.12–15 Patients in these
studies were primarily recipients of deceased-
donor kidney transplants and included those at
immunologically high risk for rejection; that is,
they were generally African-Americans, repeat
transplant recipients, patients with high levels of
panel reactive antibody, those with a prolonged
cold ischemic time, or those with delayed graft
function. Although not directly observed in
these clinical trials, which had relatively short
follow-up periods, a major concern surrounding
the use of some induction strategies is that the
risk for infections may be increased. Particular
issues are cytomegalovirus (CMV) infection,
posttransplantation lymphoproliferative disease,
and death from infection or malignancy.15–17
Because of this safety concern, together with the
high acquisition cost of induction agents, many
transplant centers limit antibody induction to
kidney transplant recipients who are perceived to
be at high risk for rejection.
In the past, recipients of kidney transplants
from living unrelated donors did not receive
antibody induction at our transplant center if
they were at low risk for rejection; these included
patients who were not of African-American
descent, those receiving primary transplants, and
those with a panel reactive antibody result below
30%. In 2003, we observed a 1-year acute
rejection rate of 57% among recipients of kidney
transplants from living unrelated donors; these
transplant recipients had not received antibody
induction. To ameliorate the high acute rejection
rate, we implemented a TMG-induction protocol
for all living unrelated-donor transplant
recipients at our transplant center on January 1,
2005.
The purpose of this study was to evaluate the
efficacy, safety, and cost of TMG induction in
adults who received kidney transplants from
living unrelated donors and who were at
immunologically low risk for rejection during the
first 12 months after transplantation.
Methods
Study Design and Patients
This was a retrospective cohort study approved
by our institutional review board. The study
population included adults aged 18 years or older
who received a primary solitary kidney transplant
from a living unrelated donor at our transplan-
tation center between January 1, 2003, and June
30, 2006. Their maintenance immunosuppression
consisted of cyclosporine microemulsion,
mycophenolate mofetil, and steroids. Patients
were excluded if they had received TMG induction
for previous transplantation, if they were African-
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American, or if they had a panel reactive antibody
result of 30% or higher.
Eligible patients were divided into a no
induction group, which underwent transplantation
between January 1, 2003, and December 31,
2004, and a TMG induction group, which
underwent transplantation between January 1,
2005, and June 30, 2006. All patients were
followed for 12 months after transplantation.
Immunosuppression and Patient Follow-up
Before 2005, only patients with a previous
kidney transplant, those of African-American
descent, or those with a panel reactive antibody
result of 30% or greater were considered to have
an immunologically high risk for rejection and,
therefore, a need for TMG induction. All other
low-risk recipients of living unrelated-donor
kidney transplants received no antibody induc-
tion until January 1, 2005, when we implemented
TMG induction for all such patients.
The induction regimen consisted of TMG 1.5
mg/kg/day given intravenously for 5 days, with
the first dose administered intraoperatively. The
dose of TMG was reduced to half for patients
with a white blood cell count of 1.5–3.0 x
103/mm3 and withheld for those with a white
blood cell count below 1.5 x 103/mm3 or platelet
count below 50 x 103/mm3.
Both the no induction and induction groups
received the same maintenance immunosuppression
with cyclosporine microemulsion, mycophenolate
mofetil, and steroids. Cyclosporine was started
at 5 mg/kg/dose given orally every 12 hours
within 24 hours after surgery. The dosage was
adjusted to maintain a morning whole-blood
trough concentration of 225–275 ng/ml for the
first month, 175–225 ng/ml for the second month,
and 125–175 ng/ml thereafter. Cyclosporine
concentrations were measured centrally by using
validated liquid chromatography with tandem
mass spectrometry, with an interrun variability
of less than 5%.18 Mycophenolate mofetil 1 g
twice/day was started 2 days before transplanta-
tion, and the dosage was reduced or temporarily
withheld for adverse effects such as gastro-
intestinal complaints, hematologic abnormalities,
or serious infections. Intravenous methyl-
prednisolone 500 mg was given intraoperatively,
and oral prednisone was tapered from 100
mg/day on postoperative day 1 to 5–10 mg/day
over 8 weeks.
All patients received CMV prophylaxis with
valganciclovir 450 mg/day for 3–6 months,
fungal prophylaxis with oral nystatin for 30 days,
and Pneumocystis jiroveci prophylaxis with
trimethoprim 80 mg–sulfamethoxazole 400 mg
for 30 days or as a one-time dose of aerosolized
pentamidine 300 mg.
During the first 12 months after kidney
transplantation, patients were followed with a
minimum of biweekly laboratory monitoring and
weekly-to-quarterly clinic visits, depending on
their clinical progress.
All episodes of clinically suspected acute
rejection were subsequently confirmed and
graded by biopsy according to the Banff 97
criteria.19 Once confirmed, borderline or Banff
1A acute rejection was treated with intravenous
methylprednisolone 250 mg for 3 days, and acute
rejection of grade Banff 1B or higher was
managed with TMG 1.5 mg/kg/day for 7–14 days.
These treatments were given on an inpatient
basis or at our outpatient infusion center,
depending on the patient’s clinical condition.
Study Assessments
From the patients’ medical records at our
hospital, we obtained data regarding recipient
and donor characteristics, graft and patient
survival, drugs, laboratory data (including
cyclosporine trough concentrations, serum
creatinine concentrations, and CMV polymerase
chain reaction assay results), results of kidney
allograft biopsy, and hospitalizations. Cost-
accounting data were obtained from the hospital’s
data warehouse. We obtained information for all
inpatient resources utilized during hospitalization
for the transplantation and for subsequent
readmissions to our hospital. Outpatient cost
data for drugs, procedures, clinical visits, and
hospitalizations to other institutions were not
obtained. Costs in the no induction group were
discounted to June 2006 dollars.20
The primary efficacy end point was the
occurrence of biopsy-proven acute rejection in
the first 12 months after transplantation.
Secondary outcomes were the severity of
rejection; occurrence of delayed graft function,
graft failure, patient death, CMV disease, and
malignancy; patients’ renal function at 12 months
after transplantation; and number of hospital-
izations during the first 12 months. Delayed
graft function was defined as a need for dialysis
within 1 week after transplantation. Disease due
to CMV was defined as CMV viremia that was
detectable with quantitative polymerase chain
reaction accompanied by viral syndrome (fever,
1168
ANTITHYMOCYTE GLOBULIN INDUCTION IN KIDNEY TRANSPLANT RECIPIENTS Miller et al
malaise or leukopenia) or organ dysfunc-tion in
the absence of other documented causes.
We collected all hospitalization data at our
transplant center from the transplantation surgery
and during the 12-month follow-up. Hospital
readmissions were divided into five categories
based on their reason: rejection, infection,
surgical complications (urine leak, ureteral
obstruction, lymphocele, or wound dehiscence),
medical complications (other than infection),
and all others.
Statistical Analysis
Categoric variables were analyzed using a 2 or
the Fisher exact test, and continuous variables
were assessed using a Student t test. All tests
were two-sided, and statistical significance was
defined at a p value of less than 0.05.
Results
Of 161 adults who received living unrelated-
donor kidney transplants at our transplant center
between January 1, 2003, and June 30, 2006, 87
were included for analysis: 40 patients in the no
induction group and 47 patients in the TMG
induction group. Baseline characteristics of
recipients and donors were similar between the
groups, except for the percentage of patients with
positive results for panel reactive antibody (Table
1). Also similar between the no induction and
induction groups were percentages of donors
older than 55 years (8% and 15%, respectively),
recipients older than 65 years (8% and 6%,
respectively), and female donor–to–male
recipient pairs (38% and 43%, respectively;
p>0.05 for all comparisons).
Induction of TMG at a mean ± SD total dose of
5.9 ± 1.3 mg/kg was administered with minimal
effect on initial hospital stays for transplantation
(median days for no induction 3.0 vs induction
4.0). According to our center’s protocol,
cyclosporine trough concentrations reached
target ranges within 7 days in both groups. Mean
± SD cyclosporine trough concentrations were
comparable between the groups at 1 month (no
induction 282 ± 73 ng/ml vs induction 259 ± 74
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Table 1. Baseline Characteristics
No Induction TMG Induction
Group Group
Characteristic (n=40) (n=47) p Value
Mean ± SD
Recipient age (yrs) 46.3 ± 11.2 50.3 ± 12.9 0.13
Donor age (yrs) 41.0 ± 9.7 44.7 ± 11.6 0.11
No. of HLA mismatches 5.1 ± 1.2 4.4 ± 1.0 0.07
HLA-A 1.5 ± 0.7 1.2 ± 0.7 0.21
HLA-B 1.8 ± 0.4 1.6 ± 0.5 0.28
HLA-DR 1.8 ± 0.6 1.5 ± 0.6 0.16
No. (%) of Patients
Female recipients 16 (40) 18 (38) 0.87
Female donors 26 (65) 29 (62) 0.75
Panel reactive antibody result 0.03
0% 36 (90) 33 (70)
1–9% 4 (10) 7 (15)
10–30% 0 (0) 7 (15)
Cause of end-stage renal disease 0.61
Diabetes mellitus 17 (43) 18 (38)
Hypertension 4 (10) 5 (11)
Polycystic kidney disease 8 (20) 6 (13)
Alport’s disease 0 (0) 3 (6)
Obstructive uropathy 4 (10) 3 (6)
Focal segmental glomerular 3 (8) 4 (9)
sclerosis
Other 4 (10) 8 (17)
Cytomegalovirus serostatus 0.93
D+/R– 10 (25) 9 (19)
D+/R+ 10 (25) 12 (26)
D–/R+ 9 (23) 12 (26)
D–/R– 11 (28) 14 (30)
TMG = rabbit antithymocyte globulin; HLA = human leukocyte antigen.
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ng/ml, p>0.05) and throughout the 12 months
after transplantation (Figure 1).
Within 12 months after kidney transplantation,
19 patients (48%) in the no induction group and
one patient (2%) in the induction group had at
least one episode of biopsy-proven acute
rejection (p<0.001; Figure 2). Of the 19 patients
in the no induction group, 14 (74%) experienced
their first rejection episodes within 30 days after
transplantation, seven (37%) had repeat rejection
episodes, and two (11%) had a third rejection
episode. Of 28 rejection episodes in the no
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Table 2. Clinical Outcomes at 12 Months After Transplantation
No Induction TMG Induction
Group Group
Outcome (n=38)a (n=44)a p Value
Serum creatinine concentration, 1.4 ± 0.3 1.5 ± 0.3 0.08
mean ± SD (mg/dl)
No. (%) of Patients
Serum creatinine concentration 10 (26) 14 (32) 0.59
> 1.5 mg/dl
Acute rejections 19 (50) 1 (2) <0.001
Severity of first rejection <0.001
Borderline 3 (8) 0 (0)
Banff 1A 5 (13) 1 (2)
Banff 1B 6 (16) 0 (0)
Banff 2A 5 (13) 0 (0)
Recurrent rejection 7 (18) 0 (0) 0.003
Graft failures 2 (5) 3 (7) >0.99
Deaths 2 (5) 2 (5) 0.63
Cytomegalovirus disease
Overall 2 (5) 3 (7) >0.99
D+/R- 1 (3) 3 (7)
D+/R+ 1 (3) 0 (0)
D-/R+ 0 (0) 0 (0)
D-/R- 0 (0) 0 (0)
Malignancies 1 (3) 1 (2) 0.71
TMG = rabbit antithymocyte globulin.
aData are based on the numbers of patients with functioning kidney transplants who were alive at 12 months.
Figure 1. Mean cyclosporine trough concentrations during
the 12 months after transplantation for the no induction
group (open circles) and the rabbit antithymocyte globulin
induction group (closed circles). Error bars indicate SDs.
Concentrations were similar at all time points between
groups (p>0.05).
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Figure 2. Proportion of patients who did not experience
biopsy-proven acute rejection during the 12 months after
transplantation in the no induction group and in the rabbit
antithymocyte globulin induction group.
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induction group, 13 episodes (46%) in 12
patients required treatment with TMG (Banff
grade 1B or higher, p<0.001 vs TMG induction
group), and 14 episodes (50%) in 13 patients
required hospitalization. The one rejection
episode (grade Banff 1A) in the induction group
was treated with methylprednisolone at the
outpatient infusion center (Table 2).
Two deaths occurred in each group. The
causes of death were brain herniation and an
accident unrelated to transplantation in the no
induction group, and hypoglycemia and sepsis in
the induction group. Two cases of graft failure
occurred in the no induction group, both of
which were due to the patient’s death. Three
cases of graft failure were observed in the
induction group; two were due to the patient’s
death, and one was due to recurrent glomeru-
lonephritis. No case of delayed graft function
occurred in either group.
Occurrences of CMV disease and malignancy
(squamous cell carcinoma in the no induction
group and renal cell carcinoma in the induction
group) were low and comparable between the
groups. No patients developed BK virus–induced
nephropathy or posttransplantation lympho-
proliferative disease. Kidney allograft function at
12 months after transplantation, as measured by
serum creatinine concentration, was not signifi-
cantly different between the groups (Table 2).
Significantly more kidney allograft biopsy
procedures were performed in the no induction
group than in the induction group (mean ± SD
1.1 ± 1.1 vs 0.5 ± 0.7/patient, p=0.007). This
finding indicated that serum creatinine concen-
trations may have fluctuated more in patients in
the no induction group than in patients in the
induction group.
During the first 12 months after transplan-
tation, 25 patients in the no induction group had
a total of 47 hospital readmissions, 30% of which
were for treatment of rejection episodes. In the
induction group, 45 hospital readmissions
occurred in 19 patients. Besides rejection, other
reasons for hospital readmission were similarly
distributed between the groups (Table 3).
Hospital resource use is reported in Table 4.
Inpatient costs were significantly higher during
the hospitalization for transplantation in the
induction group than in the no induction group
($64,722 vs $50,628; p=0.02). However, total
hospitalization costs during the first 12 months
after transplantation were comparable between
the groups (induction $74,183 vs no induction
$66,038, p>0.05). As expected because of the
use of TMG, the pharmacy cost/patient was
significantly higher in the induction group than
in the no induction group during the hospital-
ization for transplantation ($6810 vs $1528,
p<0.001).
Of note, costs associated with organ procurement
and transplanting the donor kidney were
$3636/patient higher in the induction group than
in the no induction group. The cost of nursing
care tended to be higher with induction, partially
due to one outlier in the group who required a
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Table 3. Hospital Readmissions After Initial Discharge
During 12 Months After Transplantation
No TMG
Induction Induction
Group Group
Variable (n=40) (n=47)
Total no. of readmissions 47 45
No. (%) of Readmissions
Reason for readmission
Rejection 14/47 (30) 0 (0)
Infection 9/47 (19) 14/45 (31)
Surgical 7/47 (15) 5/45 (11)
Medical 14/47 (30) 19/45 (42)
Other 3/47 (6) 3/45 (7)
No. (%) of Patients
Readmitted 25 (63) 19 (40)
≥ 2 readmissions 13 (33) 8 (17)
Median (range)
No. of readmissions/patient 2 (1–4) 1 (1–6)
Duration of hospital stay/
readmission (days) 5 (1–44) 6 (1–47)
TMG = rabbit antithymocyte globulin.
Table 4. Costs of Hospital Resource Use During 12 Months
After Transplantation
Cost/Patient ($)
No TMG
Induction Induction
Group Group
Category (n=40) (n=47) p Value
Total inpatient 66,038 74,183 >0.05
Transplant
hospitalization 50,628 64,722 0.02
Pharmacy 1528 6810 <0.001
Transplantation 39,137 42,773 <0.001
Nursing 4546 7810 >0.05
All additional 5417 7329 >0.05
Readmission 15,410 9461 >0.05
Rejection 3985 0
Infection 4359 3728
Surgical 1765 689
Medical 2841 4339
All other costs 2458 705
TMG = rabbit antithymocyte globulin.
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prolonged stay in the intensive care unit.
Although not statistically significant, the mean
readmission cost/patient tended to be lower with
TMG induction than with no induction ($9461
vs $15,410).
Discussion
We present the first comparative data regarding
the use of TMG induction versus no induction
specifically for immunologically low-risk
recipients of living unrelated-donor kidney
transplants. In particular, these are patients
receiving primary kidney transplants, those not
of African-American descent, and those with low
panel reactive antibody results. After TMG
induction was implemented, the occurrence of
acute rejection among recipients of living
unrelated-donor kidney transplants dramatically
decreased from 48% to 2%. Most rejection
episodes in patients in the no induction group
occurred early after transplantation, and about
half of the cases required TMG therapy and
hospitalization for treatment. The number of
patients needed to treat with TMG induction was
2.2 to prevent one episode of acute rejection.
This clinical benefit was achieved without
significant increases in total inpatient costs or in
occurrences of CMV disease and malignancy
during the 12 months after transplantation. We
observed no apparent differences between the
groups in terms of donor and recipient charac-
teristics or maintenance immunosuppression
levels that might have suggested that an era effect
was responsible for improving outcomes with
TMG induction.
The efficacy of TMG induction in our recipients
of living unrelated-donor kidney transplants was
similar to what was observed in controlled
clinical trials of recipients of deceased-donor
kidney transplants.12–15 Unlike recipients of
living related-donor kidney transplants,
recipients of living unrelated-donor transplants
may be at high risk for rejection partly because of
poorer matching of human leukocyte antigens
and older donors.5, 6 However, studies to address
proper management of the problem in this
specific patient population have been limited to
retrospective reviews without comparators.
A retrospective, single-center study revealed an
acute rejection rate of 9% during a mean ± SD 2.7
± 1.7–year follow-up in 68 recipients of living
unrelated-donor kidney transplants.21 The
cohort was given various TMG induction
regimens as well as a calcineurin inhibitor, an
antiproliferative agent, and steroids. A multicenter
registry, Thymoglobulin Antibody Immuno-
suppression in Living Donor Recipients
(TAILOR), involved more than 1500 living-donor
kidney transplant recipients treated with TMG
induction.22 Researchers examining this registry
observed a similarly low rejection rate of 6.4% at
12 months after transplantation, but they did not
separately report outcomes for recipients of living
unrelated-donor kidney transplants. In both
reports, TMG induction was well tolerated, with
no serious infectious or malignancy complications
observed.
Although our study design was not appropriate
to address long-term safety of TMG induction,
the short-term (12-mo) outcome was promising,
and we observed low and similar occurrences of
CMV disease in both patients in the no induction
and induction groups who received valganciclovir
prophylaxis. In another study, CMV disease was
significantly more common in patients who
received TMG induction than in those who did
not (32.5% vs 19.0%, p=0.009).12 However, the
authors did not describe whether antiviral
prophylaxis was given to their patients. We and
others have shown that the potentially increased
risk of CMV disease with TMG induction can be
overcome by using effective antiviral
prophylaxis.21, 23, 24
Another induction approach to reduce acute
rejection rates and to potentially improve safety
profiles is treatment with interleukin-2 receptor
blockers. Published data are lacking about use of
this strategy in immunologically low-risk
recipients of living unrelated-donor kidney
transplants. In deceased-donor kidney transplant
recipients, the efficacy of basiliximab induction
and calcineurin inhibitor–based triple immuno-
suppression was clearly inferior to that of TMG
induction.12, 14 In a retrospective analysis of 54
recipients of living related-donor kidney
transplants, basiliximab induction failed to show
clinical or economic benefits.25
The choice of calcineurin inhibitor for
maintenance immunosuppression varies across
the United States.1 Approximately three fourths
of kidney transplant recipients in the United
States are given tacrolimus, whereas the rest
receive cyclosporine microemulsion or no
calcineurin inhibitor. Considerable debate
surrounds the optimal choice of calcineurin
inhibitor. However, a recent randomized clinical
trial showed no significant difference between
tacrolimus-based regimens and a cyclosporine
microemulsion–based regimen.26 Also, many
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transplant centers use steroid-sparing immuno-
suppression regimens. This may limit applica-
bility of our data from living unrelated-donor
kidney transplant recipients who received
cyclosporine and steroids in addition to
mycophenolate mofetil. Conventional triple
immunosuppression consisting of tacrolimus,
mycophenolate mofetil, and steroids without
antibody induction resulted in similar but
unacceptably high rejection rates in kidney
transplant recipients from both living related
donors and living unrelated donors (57.8% and
58.8%, respectively, p>0.05).27 This observation
highlights the need for an intensified induction
approach in recipients of living unrelated-donor
kidney transplants.
As expected, the cost of the primary transplant
hospitalization was significantly higher with
TMG induction because of the higher pharmacy
costs and the increased costs of organ procurement
and the transplantation procedure. We theorize
that the increased transplantation costs were a
function of time. We observed a mean total dose
of 5.9 mg/kg for TMG induction. At this dose,
using the average wholesale price, the estimated
cost for a 70-kg patient equals $7434,28 which
can essentially account for the difference in the
pharmacy costs between the no induction and
TMG induction groups. Of note, the increased
costs associated with TMG induction during the
primary transplantation hospitalization were
eventually offset at 12 months after transplantation
by decreased costs due to fewer hospital
readmissions associated with rejection.
Whether the increased primary transplantation
hospitalization expense is cost-effective depends
on several institution-specific factors. First,
various doses of TMG for induction have been
effective.21, 22, 29–31 We administered TMG 5.9 ±
1.3 mg/kg over 5 days; however, using a total
dose lower than 6 mg/kg or administering TMG
induction over a shorter duration can reduce the
cost of the primary transplantation hospitalization.
Second, many transplant centers readmit patients
for the diagnosis and treatment of rejection. We
used outpatient procedures and outpatient
infusion centers for this purpose, which could
reduce hospital readmission costs.
Retrospective studies based on historical
control groups possess inherent limitations.
With implementation of the TMG induction
protocol at our transplant center, maintenance
immunosuppression and other patient
management protocols remained the same.
Despite this situation, it is possible that there
may have been other time-sensitive variables that
were not controlled for in our analysis. In
addition, this study had a relatively short follow-
up of 12 months and small sample sizes that may
have prevented us from detecting potential
differences in safety, especially malignancy
complications and long-term graft outcomes,
between the groups.
Another limitation was the lack of outpatient
cost data. Inclusion of outpatient costs for
kidney allograft biopsy and rejection treatment at
the outpatient procedure and infusion centers
could have further increased the total costs for
patients in the no induction group. We chose not
to include these costs because of the difficulty in
obtaining them from the various outpatient
sources without bias and because our study was
designed from the hospital’s perspective. In
addition, analyses from the perspective of
hospital margins, payer costs, direct and indirect
patient costs, and costs to society would be
valuable but were beyond the scope of this small
analysis. Although TMG induction was asso-
ciated with higher short-term costs, we hypothe-
size that the long-term benefits of reduced acute
rejection rate and hospital readmissions will offer
positive financial returns for the patient, the
payer, and society.
A large, prospective, randomized controlled
study with a long-term follow-up and complete
inpatient and outpatient cost data would be ideal
to confirm our hypotheses. However, such
studies require substantial resources and are
unlikely to be conducted for TMG induction
with established efficacy outcomes.
Conclusion
Five-day TMG induction was an effective and
safe strategy to prevent acute rejection in adult
recipients of living unrelated-donor kidney
transplants. Induction did not significantly
increase total inpatient costs during the first year
after transplantation. Induction also showed a
potential for reducing hospital readmissions and
costs associated with the diagnosis and treatment
of rejection.
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